Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives
Alberico Luigi Catapano,1,2 Angela Pirillo,1,2 Giuseppe Danilo Norata1,3,4 1Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, 2IRCCS Multimedica Hospital, Sesto San Giovanni, 3Center for the Study of Atherosclerosis, E. Bassini Hospital, Cinisello...
Main Authors: | Catapano AL, Pirillo A, Norata GD |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2017-09-01
|
Series: | Vascular Health and Risk Management |
Online Access: | https://www.dovepress.com/anti-pcsk9-antibodies-for-the-treatment-of-heterozygous-familial-hyper-peer-reviewed-article-VHRM |
Similar Items
-
Cost-Effectiveness Analysis of PCSK9 Inhibitors for the Treatment of Heterozygous Familial Hypercholesterolemia
by: Lasica, Rick, et al.
Published: (2017) -
PCSK9 Antibodies for the Treatment of Hypercholesterolemia
by: Ioanna Gouni-Berthold, et al.
Published: (2014-12-01) -
Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
by: Brian Tomlinson, et al.
Published: (2021-04-01) -
PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive Synopsis
by: Qianyun Guo, et al.
Published: (2020-09-01) -
Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia
by: R. Huijgen, et al.
Published: (2012-05-01)